Orange Grove CEO: Korean Opportunities A Priority In Global Expansion
Bridge Between US, Korean Biotech
Executive Summary
US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.
You may also be interested in...
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.
What's Keeping Korea From Adopting Decentralized Clinical Trials?
The current status of decentralized clinical trials in Korea and the country’s efforts to boost activity in this area were discussed at the recent Bio Korea meeting, with cultural and medical practices, along with technological and medical literacy, among the areas seen as affecting broader adoption of the various elements of the approach.
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.